finance.yahoo.com ·
Biocardia Inc Bcda Q1 2026
Topic context
This topic has been covered 358214 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedBioCardia (BCDA) is a development-stage biotech with a promising cardiac cell therapy. The FDA breakthrough designation and Medicare reimbursement signal potential future revenue, but the company faces severe cash constraints ($951k) and a long regulatory timeline in Japan. Commercial mechanism is weak at this stage: no approved product, no revenue, and high cash burn. The primary sector is PHARMA_BIOTECH, but impact is limited to the company itself with no broader sector effect.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- BioCardia received FDA breakthrough designation and Medicare reimbursement of $20,000 per treatment for cardiac cell therapy.
- Ongoing CARDIAMP heart failure trial showed significant improvements in heart function and quality of life.
- Japan's PMDA is considering regulatory approval with an initial market opportunity of 20,000 patients.
- BioCardia ended Q1 2026 with only $951,000 in cash.
- Regulatory process in Japan requires seven months for submission and a year for review.
